FABP4 and neoplasm: In addition, FABP4 tumor endothelial cell immunostaining was significantly lower in mice treated with BMS309403 both in the preventive group (11.3%, ranges 8.6–22.2, p = 0.02) and in the curative group (0.1%, ranges 0.09–4.5, p = 0.007) than in controls (45.9%, ranges 44.6–77.6) (Fig. 6b).